| Summary: | Margaret F Meagher,1 Amirali Salmasi,1 Tyler F Stewart2 1Department of Urology, University of California San Diego, La Jolla, CA, USA; 2Division of Hematology-Oncology and BMT, University of California San Diego, La Jolla, CA, USACorrespondence: Tyler F Stewart, Tel +1 (866) 773-2703, Email tstewart@health.ucsd.eduAbstract: With the advent of new therapeutic modalities, management of metastatic castrate-sensitive prostate cancer (mCSPC) has been in flux. From androgen-deprivation therapy to docetaxel to androgen receptor–signaling inhibitors, each agent has heralded a new treatment paradigm. As such, the optimal first-line therapy for mCSPC remains incompletely defined. This review provides a narrative of recent advances to systemic therapy within the mCSPC treatment space, particularly with regard to expansion to triplet therapy.Keywords: metastatic, castrate-sensitive prostate cancer, darolutamide
|
|---|